Research Market strategy
By Swissquote Analysts
Themes Trading

F.D.A. to Approve Pfizer Vaccine... Completely

By Peter Rosenstreich
Published on

Related theme

According to media reports (New York Times), the Food and Drug Administration is anticipated to give Pfizer Inc. and partner BioNTech SE full approval of their Covid-19 vaccine. This development will likely encourage individuals concerned about health problems to get vaccinated and public entities to require wide spread mandatory inoculation.

In December 2020, Pfizer’s two-dose regiment only got the F.D.A.’s “Green Light” on emergency use. This emergency authorization allows for distribution during a public-health crisis. This emergency designation was based on limited available data, suggesting that the full approval includes significantly more favorable data.

This follows news that the third dose, “booster,” of the vaccine has been authorized for select individuals. The Pfizer-BioNTech vaccine has shown efficacy rates against the Delta variant of 42% to 96%.